Clinical Trials · NCT00953394
5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- University of Turin, Italy
- Enrollment
- 29
- Start date
- Feb 2002
- Locations
- 7 sites, Italy
- Primary endpoint
- disease free survival